BMS-986120
Based on 1 publication(s) in Google Scholar
BMS-986120 is a first-in-class oral and reversible protease-activated receptor 4 (PAR4) antagonist, with IC50s of 9.5 nM and 2.1 nM in human and monkey blood, respectively. BMS-986120 has potent and selective antiplatelet effects.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit: 98.14%
- CAS. Nr.: 1478712-37-6
- Formel: C23H23N5O5S2
- Molecular Weight:513.59
-
Speicherung:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
-
Lösungsmittel & Löslichkeit
- Protokoll
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
-
GPCR/G Protein Compound Library
HY-L006
-
Clinical Compound Library
HY-L026
-
Anti-Cardiovascular Disease Compound Library
HY-L046
-
Coagulation and Anti-coagulation Compound Library
HY-L136
-
Heterocyclic Compound Library
HY-L138
-
Membrane Protein-targeted Compound Library
HY-L149
-
Membrane Receptor-targeted Compound Library
HY-L150
-
Highly Selective Inhibitors Library
HY-L158
-
Multi-Target Compound Library
HY-L176
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Clinical Compound Library Plus
HY-L026P
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
-
Lactylation Compound Library
HY-L249
Publications Citing Use of MedChemExpress (MCE) BMS-986120
More
Biologische Aktivität
|
PAR1 |
PAR4 |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| Platelet | IC50 |
>200 nM
Compound: 43; BMS-986120
|
Antiplatelet activity against ADP agonist peptide-induced human platelet assessed as inhibition of platelet aggregation
Antiplatelet activity against ADP agonist peptide-induced human platelet assessed as inhibition of platelet aggregation
|
[PMID: 35729784] |
| Platelet | IC50 |
>200 nM
Compound: 43; BMS-986120
|
Antiplatelet activity against collagen agonist peptide-induced human platelet assessed as inhibition of platelet aggregation
Antiplatelet activity against collagen agonist peptide-induced human platelet assessed as inhibition of platelet aggregation
|
[PMID: 35729784] |
| Platelet | IC50 |
>200 nM
Compound: 43; BMS-986120
|
Antiplatelet activity against PAR1 agonist peptide-induced human platelet assessed as inhibition of platelet aggregation
Antiplatelet activity against PAR1 agonist peptide-induced human platelet assessed as inhibition of platelet aggregation
|
[PMID: 35729784] |
| Platelet | IC50 |
>200 nM
Compound: 43; BMS-986120
|
Antiplatelet activity against U46619 agonist peptide-induced human platelet assessed as inhibition of platelet aggregation
Antiplatelet activity against U46619 agonist peptide-induced human platelet assessed as inhibition of platelet aggregation
|
[PMID: 35729784] |
| Platelet | IC50 |
17.5 nM
Compound: 43; BMS-986120
|
Antiplatelet activity against PAR4 agonist peptide-induced human platelet assessed as inhibition of platelet aggregation
Antiplatelet activity against PAR4 agonist peptide-induced human platelet assessed as inhibition of platelet aggregation
|
[PMID: 35729784] |
| Platelet | IC50 |
7.6 nM
Compound: 43; BMS-986120
|
Antiplatelet activity in human platelet-rich plasma assessed as inhibition of gamma thrombin induced platelet aggregation preincubated for 5 mins followed by gamma thrombin addition and measured upto 15 mins by plate reader assay
Antiplatelet activity in human platelet-rich plasma assessed as inhibition of gamma thrombin induced platelet aggregation preincubated for 5 mins followed by gamma thrombin addition and measured upto 15 mins by plate reader assay
|
[PMID: 35729784] |
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS. Nr. 1478712-37-6
-
Appearance Solid
-
Molecular Weight 513.59
-
Formel C23H23N5O5S2
-
Color White to off-white
-
SMILES
CC(SC(N1CCOCC1)=N2)=C2COC3=CC(OC)=CC4=C3C=C(O4)C5=CN6N=C(OC)SC6=N5
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Publications (1)
-
Journal Impact Factor
-
Most Recent
Lösungsmittel & Löslichkeit
DMSO : 3.33 mg/mL (6.48 mM; ultrasonic and warming and heat to 80°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Protokoll
Monkeys[1]
Individual anesthetized monkeys are given orally of BMS-986120 (BMS: 0.2, 0.5,1 mg/kg) or vehicle (n=8/group) 2 hour before a combination of thrombosis, BT and ex vivo biomarker experiments. Aspirin alone (ASA, 4 mg/kg/h IV) or in combination with BMS-986120 (0.5, 1 mg/kg) is also studied (n=8/group). Thrombus weight (TW) reduction, BT increase over vehicle in kidney (KBT) and mesenteric artery (MBT), and platelet aggregation (PA) inhibition are determined. Peak PA responses to activation peptides selective for PAR4 (PAR4-AP, 12.5 μM) and PAR1 (PAR1-AP, 18 μM), ADP (20 μM), and collagen (5 μg/mL) are determined by whole blood aggregometry[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Reinheit & Dokumentation
-
Data Sheet (277 KB)
-
SDS (557 KB)
- English - EN (557 KB)
- Français - FR (557 KB)
- Deutsch - DE (557 KB)
- Norwegian - NO (557 KB)
- Español - ES (557 KB)
- Swedish - SV (557 KB)
- Italian - IT (557 KB)
- Korean - KR (557 KB)
- Portuguese - PT (557 KB)
-
Handling Instructions (2659 KB)
Verweise
[2]. Wilson SJ, et al. PAR4 (Protease-Activated Receptor 4) Antagonism With BMS-986120 Inhibits Human Ex VivoThrombus Formation. Arterioscler Thromb Vasc Biol. 2018 Feb;38(2):448-456. [Content Brief]
[3]. Wong PC, et al. Blockade of protease-activated receptor-4 (PAR4) provides robust antithrombotic activity with low bleeding. Sci Transl Med. 2017 Jan 4;9(371). [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.9471 mL | 9.7354 mL | 19.4708 mL | 48.6770 mL |
| 5 mM | 0.3894 mL | 1.9471 mL | 3.8942 mL | 9.7354 mL |
BMS-986120 Related Classifications
HY-19837 Related Classifications
Powered by Bioz